Bronwyn Mixter

10PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Food properties (incl. characteristics and health benefits)Environmental epidemiologyMolecular targetsFlight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Yufan Liu, Jeannette Nashed, Amy K Barone

|Aug 05, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

Asma Dilawari, Hui Zhang, Mirat Shah

|Aug 19, 2024
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.

Asma Dilawari, James Buturla, Christy Osgood

|Feb 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Mirat Shah, Hima Lingam, Xin Gao

|Dec 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco

|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari, Mirat Shah, Gwynn Ison

Pageof 2

Frequent Collaborators

10 joint publications

Richard Pazdur

7 joint publications

Shenghui Tang

7 joint publications

Laleh Amiri-Kordestani

4 joint publications

Mirat Shah